title: Corneal sensitivity changes following the instillation of latanoprost, bimatoprost, and travoprost eyedrops.
abstract: OBJECTIVE
  To examine central corneal mechanical sensitivity (CCMS) after the instillation of latanoprost, travoprost, and bimatoprost.
  
  
  METHODS
  Nonrandomized interventional study.
  
  
  METHODS
  Latanoprost was used in 24 patients (43 eyes), travoprost in 21 patients (42 eyes), and bimatoprost in 15 patients (28 eyes). CCMS was examined with the Cochet-Bonnet esthesiometer before the instillation of prostaglandin analogs and then 5 and 30 minutes later. Examination of Schirmer and breakup time (BUT) tests were also performed. Thirty healthy subjects were examined as a control group.
  
  
  RESULTS
  CCMS was significantly reduced at the 5-minute interval for latanoprost (P = .03), travoprost (P = .04), and bimatoprost (P = .04). Differences between the three analogs were statistically not significant. CCMS changes significantly correlated with Schirmer and BUT test scores.
  
  
  CONCLUSIONS
  The correlation between CCMS reduction and BUT and Schirmer test scores implies that the use of artificial tears may be considered if prostaglandin analogs are administered.
authors.affiliation: Department of Ophthalmology, Democritus University of Thrace, Thrace, Greece.
authors.forename: Vassilios P
authors.initials: VP
authors.lastname: Kozobolis
authors.forename: Efstathios T
authors.initials: ET
authors.lastname: Detorakis
authors.forename: George
authors.initials: G
authors.lastname: Maskaleris
authors.forename: Stavroula C
authors.initials: SC
authors.lastname: Koukoula
authors.forename: Nikitas
authors.initials: N
authors.lastname: Fountoulakis
authors.forename: Fotios
authors.initials: F
authors.lastname: Chrysochoou
authors.forename: Anastasios G
authors.initials: AG
authors.lastname: Konstas
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000577:Amides; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000069580:Bimatoprost; D003008:Cloprostenol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D003315:Cornea / Q000187:drug effects* / Q000502:physiology; D005260:Female; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008055:Lipids / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000009:adverse effects; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000009:adverse effects; D012677:Sensation / Q000187:drug effects* / Q000502:physiology; D012678:Sensation Disorders / Q000139:chemically induced* / Q000503:physiopathology; D000069557:Travoprost
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D008055:Lipids; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D000069580:Bimatoprost; D000069557:Travoprost